Neuropathy Partnering - 2009-2014





Published: August 2014 | Pages: 100+ | Format: PDF

The Neuropathy Partnering 2009-2014 report provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in neuropathy partnering deals
  • Top neuropathy deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type

 

The Neuropathy Partnering 2009-2014 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This data driven report contains over 35 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of neuropathy partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in neuropathy partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading neuropathy deals since 2009. Deals are listed by headline value, signed by bigpharma, most active of all bio pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of neuropathy partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of neuropathy technologies and products.

 

Report scope 

 

Neuropathy Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to neuropathy trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

  • Trends in neuropathy dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • The leading neuropathy deals by value since 2009

 

In Neuropathy Partnering 2009-2014, the available deals are listed by:

 

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


 

Executive Summary 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in neuropathy partnering 

 

2.1. Introduction
2.2. Neuropathy partnering over the years
2.3. Bigpharma neuropathy dealmaking activity
2.4. Neuropathy partnering by deal type
2.5. Neuropathy partnering industry sector
2.6. Neuropathy partnering by stage of development
2.7. Neuropathy partnering by technology type
2.8. Disclosed financial deal terms for neuropathy partnering
2.8.1 Neuropathy headline values
2.8.2 Neuropathy upfront payments
2.8.3 Neuropathy milestone payments
2.8.4 Neuropathy royalty rates

 

Chapter 3 – Leading neuropathy deals 

  • 3.1. Introduction
  • 3.2. Top neuropathy deals by value
  • 3.3. Top neuropathy deals involving bigpharma

 

Chapter 4 – Dealmaking directory 

 

4.1. Introduction


4.2. Company A-Z


4.3. By deal type

  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination

4.4. By industry sector

  • Academic
  • Bigpharma
  • Biotech
  • Drug delivery
  • Medical device
  • Diagnostic
  • Generic pharma
  • Government
  • Non-profit
  • Pharmaceutical
  • Research tools
  • Services
  • Specialty pharma

4.5. By stage of development

  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
  • 4.6. By technology type
  • Analysis
  • Animal models
  • Assays
  • Bioinformatics
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Cell culture
  • Cell therapy
  • Clinical testing
  • Diagnostic - companion
  • Devices
  • Diagnostics
  • Discovery tools
  • DNA probes
  • Drug delivery
  • Enabling technology
  • Epigenetics
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Industrial chemicals
  • In vitro models
  • Monoclonal antibodies
  • Nanotechnology
  • Oligonucleotide
  • Peptides
  • Personalised medicine
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

 

Chapter 5 – Partnering resource center 

 

  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking

 

Appendices 

 

Appendix 1 – Deal type definitions

 

About Wildwood Ventures 

 

  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form – Reports

 

Table of figures 

 

  • Figure 1: Neuropathy partnering since 2009
  • Figure 2: Bigpharma – top 50 – Neuropathy deals 2009 to 2014
  • Figure 3: Bigpharma neuropathy deal frequency – 2009 to 2014
  • Figure 4: Neuropathy partnering by deal type since 2009
  • Figure 5: Neuropathy partnering by industry sector since 2009
  • Figure 6: Neuropathy partnering by stage of development since 2009
  • Figure 7: Neuropathy partnering by technology type since 2009
  • Figure 8: Neuropathy deals with a headline value
  • Figure 9: Neuropathy deals with upfront payment values
  • Figure 10: Neuropathy deals with milestone payments
  • Figure 11: Neuropathy deals with royalty rates, %
  • Figure 12: Top neuropathy deals by value since 2009
  • Figure 13: Top neuropathy deals signed by bigpharma value since 2009
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions